| P50 | author | Stéphane de Botton | Q57031523 |
| P2093 | author name string | Philippe Rousselot | |
| | Pascale Cony-Makhoul | |
| | Hassan Farhat | |
| | Mathilde Ruggiu | |
| | David Ghez | |
| | Victoria Raggueneau | |
| | Diane Lara | |
| | Isabel Garcia | |
| | Christine Terre | |
| | Sophie Rigaudeau | |
| | Stéphanie Ghez | |
| | Noémie de Gunzburg | |
| | Marc Spentchian | |
| | Omar Benbrahim | |
| | Anne L Taksin | |
| | Florence Beckeriche | |
| | Florence Oberkampf | |
| | Isabelle Cano | |
| P2860 | cites work | Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias | Q28246193 |
| | Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortened survival in chronic myelogenous leukemia | Q33961765 |
| | Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. | Q34596305 |
| | The role of stem cell transplantation for chronic myelogenous leukemia in the 21st century | Q35634865 |
| | Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse | Q36835063 |
| | European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. | Q37026032 |
| | Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. | Q37086937 |
| | Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily | Q37194640 |
| | Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up | Q38386719 |
| | Management of chronic myeloid leukemia in blast crisis | Q38392682 |
| | Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population | Q38850383 |
| | Advanced phase chronic myeloid leukaemia (CML) in the tyrosine kinase inhibitor era - a report from the Swedish CML register | Q39591396 |
| | Genome-wide identification of aberrantly methylated promoter associated CpG islands in acute lymphocytic leukemia. | Q39975102 |
| | Next-generation sequencing identifies major DNA methylation changes during progression of Ph+ chronic myeloid leukemia | Q42330162 |
| | Methylation patterns in CD34 positive chronic myeloid leukemia blast crisis cells | Q42765023 |
| | Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. | Q43977683 |
| | Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase | Q43977685 |
| | Intensive chemotherapy in patients with chronic myelogenous leukaemia (CML) in accelerated or blastic phase--a report from the Swedish CML Group | Q44117294 |
| | Epigenetic profiling in chronic lymphocytic leukemia reveals novel methylation targets | Q44826936 |
| | Clinical efficacy of second generation tyrosine kinase inhibitor and 5-azacytidine combination in chronic myelogenous leukaemia in myeloid blast crisis | Q47723259 |
| | The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study). | Q53292543 |
| | Response to therapy is independently associated with survival prolongation in chronic myelogenous leukemia in the blastic phase | Q53393938 |
| | Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients | Q53416067 |
| | Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia | Q53440049 |
| | Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis | Q58023968 |
| P433 | issue | 7 | |
| P304 | page(s) | 1659-1665 | |
| P577 | publication date | 2017-11-28 | |
| P1433 | published in | Leukemia & Lymphoma | Q6534493 |
| P1476 | title | Azacytidine in combination with tyrosine kinase inhibitors induced durable responses in patients with advanced phase chronic myelogenous leukemia | |
| P478 | volume | 59 | |